Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

541747

registered interest
date	21/07/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Blood: Contamination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government whether they provide a lower level of support for the surviving partners of those infected by hepatitis C through contaminated blood, compared to the surviving partners of those infected by HIV or co-infected, and if so, why.
tabling member printed	Baroness Randerson
uin	HL1424
answer	answer is ministerial correction date of answer 26/07/2016 answer text <p>Under the reformed ex-gratia payment scheme for infected blood announced on 13 July 2016, the partner/spouse at the time of death of a primary beneficiary will be entitled to a £10,000 one-off lump sum where HIV or hepatitis C infection contributed to the death of their partner/spouse. This will apply to those already bereaved, provided they register before the end of this financial year. Anyone newly bereaved from this year will automatically receive the lump sum. Discretionary support, in an enhanced form from financial year 2018/19, will continue to be available to all bereaved partners/spouses.</p> answering member printed Lord Prior of Brampton question first answered 26/07/2016 13:22:10 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	4230 label Biography information for Baroness Randerson

541748

registered interest
date	21/07/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	HIV Infection: Drugs
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what powers the Secretary of State has to direct NHS England to commission the use of pre-exposure prophylaxis.
tabling member printed	Lord Scriven
uin	HL1425
answer	answer is ministerial correction date of answer 26/07/2016 answer text <p>Work on pre-exposure prophylaxis (PrEP) is on-going and the National Institute for Health and Care Excellence (NICE) has been asked to conduct an evidence review of Truvada for PrEP in groups at high risk of HIV. The NICE evidence summary will inform a pilot programme that will see £2 million invested over the next two years to target those at highest risk of HIV. This evidence review and pilot programme signifies the next steps forward and will inform any subsequent decisions about commissioning PrEP.</p> answering member printed Lord Prior of Brampton question first answered 26/07/2016 13:20:07 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	4333 label Biography information for Lord Scriven

541749

registered interest
date	21/07/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	HIV Infection: Drugs
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what modelling has been undertaken to investigate the effect of pre-exposure prophylaxis being made available to homosexual men to prevent the transmission of HIV, and what were the results of that modelling in terms of lives saved, healthy years gained and savings to the NHS and other public services.
tabling member printed	Lord Scriven
uin	HL1426
answer	answer is ministerial correction date of answer 26/07/2016 answer text <p>The National Institute for Health and Care Excellence is developing an evidence summary on the use of Truvada for pre-exposure prophylaxis that is expected to be published in the autumn. The evidence summary will consider the evidence for effectiveness, safety, patient factors and resource implications.</p> answering member printed Lord Prior of Brampton question first answered 26/07/2016 13:20:33 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	4333 label Biography information for Lord Scriven

541750

registered interest
date	21/07/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	HIV Infection: Health Services
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government how much was spent on treatment by AIDS and HIV services in 2011–12, 2012–13 and 2013–14.
tabling member printed	Lord Scriven
uin	HL1427
answer	answer is ministerial correction date of answer 26/07/2016 answer text <p>According to National Health Service data, the following is the estimated expenditure in relation to HIV treatment and care services:</p><p> </p><p>2011-12 - £642 million</p><p>2012-13 - £630 million</p><p>2013-14 - £570 million</p><p> </p><p>Data for financial years 2011/12 and 2012/13 are from NHS programme budgeting estimates. Data for financial year 2013/14 are a combination of programme budgeting estimates and NHS England expenditure data on specialised services. Data between these years are not comparable, as responsibility for the commissioning of some services relating to HIV and AIDS and related public health services transferred from primary care trusts (PCTs) to local authorities on 1 April 2013, and are therefore excluded from NHS figures from this date forward. In addition, price reductions and the availability of generic HIV medicines has seen the per patient spend on treatment reduce in 2013/14, despite an overall increase in the number of patients requiring care and treatment.</p><p> </p><p>In addition, data between these years are not comparable, as responsibility for the commissioning of some services relating to HIV and AIDS and related public health services transferred from PCTs to local authorities on 1 April 2013, and are therefore excluded from NHS figures from this date forward.</p><p> </p><p>Information on spend by local authorities on HIV prevention is not collected centrally. Public Health Resource Allocation (RA) returns from local authorities identified £82,658,000 was spent on sexual health advice, prevention and promotion in 2015/16 and some of this funding will have been allocated to HIV prevention activities.</p> answering member printed Lord Prior of Brampton grouped question UIN HL1428 question first answered 26/07/2016 13:24:23 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	4333 label Biography information for Lord Scriven

541751

registered interest
date	21/07/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	HIV Infection: Health Services
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government how much has been spent on AIDS and HIV services by local authorities in 2011–12, 2012–13 and 2013–14.
tabling member printed	Lord Scriven
uin	HL1428
answer	answer is ministerial correction date of answer 26/07/2016 answer text <p>According to National Health Service data, the following is the estimated expenditure in relation to HIV treatment and care services:</p><p> </p><p>2011-12 - £642 million</p><p>2012-13 - £630 million</p><p>2013-14 - £570 million</p><p> </p><p>Data for financial years 2011/12 and 2012/13 are from NHS programme budgeting estimates. Data for financial year 2013/14 are a combination of programme budgeting estimates and NHS England expenditure data on specialised services. Data between these years are not comparable, as responsibility for the commissioning of some services relating to HIV and AIDS and related public health services transferred from primary care trusts (PCTs) to local authorities on 1 April 2013, and are therefore excluded from NHS figures from this date forward. In addition, price reductions and the availability of generic HIV medicines has seen the per patient spend on treatment reduce in 2013/14, despite an overall increase in the number of patients requiring care and treatment.</p><p> </p><p>In addition, data between these years are not comparable, as responsibility for the commissioning of some services relating to HIV and AIDS and related public health services transferred from PCTs to local authorities on 1 April 2013, and are therefore excluded from NHS figures from this date forward.</p><p> </p><p>Information on spend by local authorities on HIV prevention is not collected centrally. Public Health Resource Allocation (RA) returns from local authorities identified £82,658,000 was spent on sexual health advice, prevention and promotion in 2015/16 and some of this funding will have been allocated to HIV prevention activities.</p> answering member printed Lord Prior of Brampton grouped question UIN HL1427 question first answered 26/07/2016 13:24:23 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	4333 label Biography information for Lord Scriven

541752

registered interest
date	21/07/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	HIV Infection: Health Services
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government how much has been spent by Public Health England on AIDS and HIV services in 2012–13, 2013–14 and 2014–15.
tabling member printed	Lord Scriven
uin	HL1429
answer	answer is ministerial correction date of answer 26/07/2016 answer text <p>Since 2013, AIDS and HIV treatment and care services have been commissioned by NHS England specialist commissioning groups.</p><p> </p><p>Between 2012 and 2015, national HIV prevention activities were funded by the Department. The information is shown in the following table.</p><p> </p><table><tbody><tr><td><p>Year</p></td><td><p>Spend</p></td></tr><tr><td><p>July 2012- March 2013</p></td><td><p>£1,835,500</p></td></tr><tr><td><p>2013/2014</p></td><td><p>£2,450,000</p></td></tr><tr><td><p>2014/2015</p></td><td><p>£2,450,000</p></td></tr></tbody></table> answering member printed Lord Prior of Brampton question first answered 26/07/2016 13:24:48 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	4333 label Biography information for Lord Scriven

541753

registered interest
date	21/07/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer: Medical Treatments
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what assessment they have made of the fact that some NHS Trusts are no longer required to meet the 62-day cancer treatment target in terms of survival rates of different types of cancer.
tabling member printed	Lord Scriven
uin	HL1430
answer	answer is ministerial correction date of answer 26/07/2016 answer text <p>The cancer waiting times standards have not changed. All trusts are still required to meet the 62-day standard.</p> answering member printed Lord Prior of Brampton question first answered 26/07/2016 13:18:31 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	4333 label Biography information for Lord Scriven

541185

registered interest
date	20/07/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Emtricitabine/Tenofovir Disoproxil
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government, further to the Written Answer by Lord Prior of Brampton on 13 July (HL1006), whether they have any plans to monitor private access to (1) Truvada for pre-exposure prophylaxis (PrEP) from clinics within England, and (2) generic versions of Truvada for PrEP online from overseas.
tabling member printed	Lord Black of Brentwood
uin	HL1349
answer	answer is ministerial correction date of answer 25/07/2016 answer text <p>It would not be possible or practical to monitor how individuals choose to access medicines or services outside of the National Health Service or to assess the impact on that individual. Registered pharmacies that operate online and that may supply drugs for use as pre-exposure prophylaxis (PrEP) are the responsibility of the General Pharmaceutical Council. We are aware that some local authority commissioned sexual health services are offering monitoring of the pharmacological efficacy of generic PrEP however this is a matter for local decision.</p> answering member printed Lord Prior of Brampton grouped question UIN HL1350 HL1351 question first answered 25/07/2016 10:46:08 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	4171 label Biography information for Lord Black of Brentwood

541186

registered interest
date	20/07/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Emtricitabine/Tenofovir Disoproxil
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what assessment they have made of the risks to individual and public health of significant numbers of individuals accessing generic versions of Truvada for pre-exposure prophylaxis online from overseas.
tabling member printed	Lord Black of Brentwood
uin	HL1350
answer	answer is ministerial correction date of answer 25/07/2016 answer text <p>It would not be possible or practical to monitor how individuals choose to access medicines or services outside of the National Health Service or to assess the impact on that individual. Registered pharmacies that operate online and that may supply drugs for use as pre-exposure prophylaxis (PrEP) are the responsibility of the General Pharmaceutical Council. We are aware that some local authority commissioned sexual health services are offering monitoring of the pharmacological efficacy of generic PrEP however this is a matter for local decision.</p> answering member printed Lord Prior of Brampton grouped question UIN HL1349 HL1351 question first answered 25/07/2016 10:46:08 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	4171 label Biography information for Lord Black of Brentwood

541187

registered interest
date	20/07/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Emtricitabine/Tenofovir Disoproxil
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government whether individuals using generic versions of Truvada for pre-exposure prophylaxis (PrEP) obtained online from overseas can access free at the point of need the appropriate monitoring and tests that are required, including as necessary tests for the pharmacological efficacy of the generic drugs they are taking, even though Truvada for PrEP has not been commissioned by NHS England.
tabling member printed	Lord Black of Brentwood
uin	HL1351
answer	answer is ministerial correction date of answer 25/07/2016 answer text <p>It would not be possible or practical to monitor how individuals choose to access medicines or services outside of the National Health Service or to assess the impact on that individual. Registered pharmacies that operate online and that may supply drugs for use as pre-exposure prophylaxis (PrEP) are the responsibility of the General Pharmaceutical Council. We are aware that some local authority commissioned sexual health services are offering monitoring of the pharmacological efficacy of generic PrEP however this is a matter for local decision.</p> answering member printed Lord Prior of Brampton grouped question UIN HL1349 HL1350 question first answered 25/07/2016 10:46:08 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	4171 label Biography information for Lord Black of Brentwood